AXL and neoplasm: In NSCLC, miR-34a was found to inhibit tumor genesis via targeting SIRT6 (Ruan et al., 2018), hindering cell viability, inducing apoptosis, and blocking cell-cycle progress through epidermal growth factor receptor (EGFR) (Yin et al., 2013) and to modulate ionizing radiation-induced senescence via targeting c-MYC and regulating gefitinib-acquired resistance via targeting Axl.